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Summary
Oral immunization with an attenuated Salmonella typhimurium recombinant containing the full-
length Plasmodium berghei circumsporozoite (CS) gene induces protective immunity against
P. berghei sporozoite challenge in the absence of antibody. We found that this immunity was
mediated through the induction of specific CD8+ T cells since in vivo elimination of CD8+
cells abrogated protection. In vitro studies revealed that this Salmonella-P . berghei CS recombinant
induced class I-restricted CD8+ cytotoxic T cells that are directed against the P berghei CS
peptide epitope spanning amino acids 242-253. This is the same peptide that previously was
identified as the target of cytotoxic T lymphocytes (CTL) induced by sporozoite immunization.
Salmonella-P.fkiparum CS recombinants were constructed that contained either the full-length
CS gene or a repeatless gene consisting of CS flanking sequences. Both of these vaccines were
able to induce CD8+ CTL directed against P . fakiparum CS peptide 371-390, which is identical
to the target of CTL induced by sporozoites and vaccinia CS recombinants. These results directly
demonstrate the ability of an intracellular bacteria such as Salmonella to induce class I-restricted
CD8+ CTL and illustrate the importance of CD8+ CTL in immunity to malaria.
M
alaria occurs in hundreds of millions ofpeople and kills
one to two million children every year (reviewed in
reference 1). A vaccine to prevent malaria is needed because
control measures, including the use of antibiotics and insec-
ticides, have been ineffective in most parts of the developing
world. Under experimental conditions, humans have been
protected from Plasmodiumfkiparum malaria by immuniza-
tion with the bites of hundreds of infected mosquitoes that
have been irradiated (2). Animals can also be immunized in
this manner or by the direct injection of radiation-attenuated
sporozoites (3). This protection is mediated in part by anti-
bodies, some of which are directed against the repeat region
of the circumsporozoite (CS)l protein, which covers the
sporozoite surface (4-7). Early animal experiments, however,
also demonstrated that 1A-suppressed mice, which lack B cells
and circulating Igs, could be immunized with radiation-
attenuated sporozoites, indicating that T cells alone are
sufficient for sporozoite-induced immunity in mice (8). This
cellular immunity is more potent than antibody against the
' Abbreviations used in this paper: CS, circumsporozoite; MF, microfluoro-
metry; RLF, repeatless fragment.
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repeat region ofthe circumsporozoite protein in terms of the
numbers of sporozoites that can be protected against (9).
Recent work has shown that in some mouse strains after
immunization with radiation-attenuated sporozoites, CD8+
T cells (cytotoxic/suppressors) are induced that are involved
in protection against malaria. Protection can be eliminated
by in vivo depletion of CD8+ T cells (10, 11) . CTL from
P . berghei-immunized mice recognize the CS protein on the
surface of infected hepatocytes and eliminate these cells from
the culture in a genetically restricted manner (12). P.fkiparum
sporozoites have been shown to induce circumsporozoite pro-
tein-specific CD8+ CTL (13), and the epitope these CTL
are directed against has been mapped to amino acid position
370-391. More recently, cloned cytotoxic T cell lines directed
against P. berghei CS protein (position 249-260) have been
shown to passively transfer protection against challenge (14).
We have previously reported that an orally administered
live attenuated Salmonella recombinant vaccine, which ex-
pressed the full-length P. berghei circumsporozoite antigen,
protected mice against malaria (15). Because the protection
was achieved in the absence of antibody, we postulated that
cellular immune mechanisms were involved. We proposed
that intracellular targeting of the Salmonella recombinant or-
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in association with class I MHC molecules with the subse-
quent induction of specific CTL. To test this hypothesis, we
constructed Salmonella typhimurium-P berghei CS andS. typhi-
murium-P . falciparum CS recombinants, immunizedmice, and
tested for CS-specific CTL. We now report that orally ad-
ministered Salmonella-CS recombinants induce CS-specific
CTL. In vivo depletion experiments demonstrate that these
CS-specific CTL are responsible for the protection against
P berghei.
Materials and Methods
Plasmids. pADE171 (16) was kindly provided by Dr. David
Hone, University ofMaryland (Baltimore, MD), andpMGB2 (15),
plasmid AROR-16 csp, and plasmidAR58 repeatless/NS (Gross,
M., D.R. Sylvester, G.Sathe, andT Theisen, manuscript submitted
forpublication) were from theDepartment of Molecular Genetics,
Smith Kline Laboratories (Swedeland, PA).
Bacteria.
￿
S. typhimurium LB 5010 r-m*, S typhimurium WR4024
trp R- were the generous gifts of Dr. Louis Baryon, Walter Reed
Army Institute of Research (Washington, DC).
Construction ofSalmonella-P. berghei CS Recombinants.
￿
The full-
length CS gene ofP. berghei strain NK65 was cloned in the Stul
restriction site of the PL-based plasmid expression vector, pMG27
NSterm, as described elsewherein detail (17, 18). In Escherichia coli,
pMGB2 expressesfull-length CS protein with sixadditional amino
acids at its NH2 terminus (Met, Asp, Pro, Trp, Arg, Lys). Plasmid
pMGB2 was purified (19) and transformed into Salmonella typhimu-
rium WR 4024 trp R-. This strain is a derivative of WR4017,
which was previously known as strain M206, an avirulent strain
with impaired ability to multiply within macrophages (20, 21).
Ampicillin-resistant colonies were examined for the expression of
P . berghei CS antigen.
Construction ofSalmonella-P.fakiparum CS Recombinants.
￿
R16
CSP, containing 16 repeats of the CS repeat region fused to the
full-length CS gene ofP.falciparum, strain 7G8, andNS 181 repeat-
less fragment (RLF), containing thefirst 81 aminoacids ofinfluenza
NS 1 protein fusedto theCS gene containing no repeat sequences
(RLF), were digested by Bg1II and Sall from plasmids AR 13R-16
csp and AR 58 repeatless/NS, respectively (Gross, M., D.R. Syl-
vester, G. Sathe, andT Theisen, manuscript submitted forpubli-
cation). The gel-purified inserts R16 CSP and NS 181 RLF were
blunt-endligatedinto thePstI site of plasmidpADE171(16), which
carries the his OGDregion ofS. typhimurium, resulting in plasmids
containing the malaria gene flanked by S. typhimurium his OGD
sequences (Fig. 1, Table 1). Plasmids pADE171 R16 and pADE171
RLF were purified and used to transform strain LB 5010, which
is an r-m* S. typhimurium strain. Spectinomycin-resistant colonies
were examined for the expression of CS gene.
PlasmidpMGB2, pADE171 R16, andpADE171 RLF were trans-
formed into S. typhimurium WR4024 trp R- by a modification
(22) of standard methods (23). Transformants WR4024/pMGB2
expressing P. berghei CS were identified by mAb 3.28 1 (24).
Salmonella transformants WR4024/pADE171 R16andWR4024/
pADE171 RLF were examined for the expression of P. fakiparum
CS antigen using mAb 49.41) 9.1 and rabbit antirepeatless anti-
body 579.15, respectively. mAb49.4D 9.1 (IgG)was made against
thefull-length CS gene by Dr. K. Esser, Walter Reed Army Insti-
tute ofResearch. Polyclonal rabbit sera raised against theCS repeat-
less molecule NS 1 81RLF 9was a kind gift of Dr. D.M. Gordon
(Walter Reed Army Institute of Research).
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Immunization Protocol.
￿
BALB/c (H2d) or B10.BR (H2t) female
mice, 5-6 wk old, were immunized with Salmonella-P. berghei or
Salmonella-P. falciparum CS recombinants, respectively. Mice were
immunized orally with three doses of 10' Salmonella CS recom-
binants on alternate days. Salmonella were cultured from liver
homogenates for up to 3 wk.
Challenge.
￿
4wk afterprimaryimmunization with Salmonella-
P. berghei CS recombinants, mice were injected intravenously with
1,000 NK65 P . berghei sporozoites. Thin blood films were made
everydaybeginning5dafterchallenge, Giemsa stained, and scanned
for parasites in 50 oil immersion fields. Mice were considered pro-
tected ifno parasites were detected by day21 afterchallenge. Serum
was collectedfrom individual mice, andanti-CS antibody was de-
tected using an ELISA (15).
Depletion ofTLymphocytes.
￿
Groups of BALB/c mice immunized
either with WR 4024/pMGB2 or WR4024,or unimmunizedmice,
were depleted of CD8' T cells or CD4` T cells by the method
of Weiss et al. (10). Briefly, 4 wk after the immunization, mice
were injected intraperitoneally with 300,ug ofanti-CD8 antibody
anti-Lyt-2.2 hybridomaclone 19/178 (mouse IgG2a) (25), or anti-
CD4 antibody, anti-L3T4 cloneGK 1.5 (rat IgG 2b (26) for four
successive days. These antibodies were purchasedfrom Bioproducts
for Science, Inc. (Madison, WI), and were kindly purified by Dr.
Walter Weiss, Naval Medical Research Institute, Rockville, MD.
3 dafter thelast depletion dose, spleen cells from antibody-treated
mice were stained with FITC-conjugated goat anti-mouse IgG2a
or goat anti-rat IgG2b (Kierkegaard & Perry Laboratories, Inc.,
Gaithersburg, MD). Depletion was quantitated by microfluorom-
etry (MF). Mice were challenged with 1,000 NK65 P berghei
sporozoites intravenously on the fourth day of depletion. These
mice received additional injections of 300 Ftgof anti-CD8 or anti-
CD4 antibody every third day for 21 d after challenge. A control
group of mice received the same dose of a mouse IgG2a on the
same schedule.
CTL AssayforP. berghei Experiments.
￿
TheCTLassaywas per-
formed as described by Townsend et al. (27). Spleen cells from
WR4024/pMGB2, WR4024, or sporozoite-immunized BALB/c
mice (haplotype H-2d) were stimulated in vitro in the presence of
various concentrations of the five different P. berghei CS peptides
listed in Table2. Cells were harvestedafter6 din culture, counted,
and incubated for 6 h at E/T ratios from 2:1 to 50:1 with 5,000
5'Cr-labeled P815 (haplotype H-2d) or EL4 (haplotype H-2b) target
cells in the presence of each individual peptide. Controls included
incubation with 5'Cr-labeled cells in the absence of peptide. After
6 h of incubation at 37°C, the plates were centrifuged, and 100
ul of supernatant was removed to measure chromium release. Per-
cent lysis was determined as 100x (experimentalcpm - medium
control cpm)/(detergent-released cpm - medium control cpm).
CTL Assays for P. fakiparum Experiments.
￿
The methods used
for cytotoxicity assays and to identify peptide target epitope(s) in
P. fakiparum CS protein were essentially the same as described by
Kumaret al. (13). Spleen cells (5 x 106) from B10.BR (H-2t) mice
immunized orally with WR4024/pADE171 R16, WR4024/
pADE171 RLF, WR4024, or recombinant vaccinia (V-71) were in-
cubated with 2 x 105 CS-transfected L cells or with 2 x 105 un-
transfected Lcells. Cellswere harvested after6 dinculture, counted,
and incubated for 6 h at various E/T ratios with 5,000 "Cr-
labeled CS-transfected Lcells or labeled untransfected L cells. Per-
cent specific lysis was determined as described above.
To identify theCTLepitope, spleen cellsfrom immunized mice
were stimulated in vitro with CS-transfected L cellsfor6 d. Puta-
tive CTLwere then incubated with untransfected L cells at an E/T
ratio of 40:1 for 6 h in the presence of various concentrations ofpeptide 371-390 (DELDYENDIEKKICKMEKCSS). Peptide res-
idue 291-310 was used as control. Killing was measured in 100
pl of supernatant as described above.
To demonstrate that CS-specific CTL were CD8+ cells, CS-
specific CTL were incubated with anti-CD8 mAb (clone 19/178)
(25) followed by complement. Washed cells were then stained with
FITC-conjugated goat anti-mouse IgG2a, and depletion was quan-
titated by microfluorimetry. Cells were incubated with 5,000 s'Cr-
labeled transfected L cells or untransfected L cells for 6 h at various
E/T ratios. The percent lysis oftarget cells bycomplement-treated
or CD8-depleted CTL was determined.
Results
For construction ofSalmonella-P . berghei CS recombinants,
expression plasmid pMGB2 containing the full-length P. ber-
ghei CS gene was transformed into S. typhimurium WR4024,
an avirulent strain. Ampicillin-resistant transformants were
examined for the expression of the CS protein. One of the
transformants, WR4024/pMGB2, expressing P berghei CS
protein, was selected for further studies (Table 1) .
For construction of Salmonella-P. falciparum CS recom-
binants, plasmid pADE171 R16 containing the full-length
P.falciparum CS gene and plasmid pADE171 RLF containing
the flanking regions without the repeats were constructed
(Fig. 1). The plasmids were transformed into S. Typhimurium
WR4024, and spectinomycin-resistant transformants were
examined for expression of CS antigens. Two of these trans-
formants were picked for further studies (Table 1).
Protection studies were performed by immunization of
BALB/c mice with Salmonella-P. berghei CS recombinants.
Mice were immunized orally with WR4024/pMGB2 or
WR4024 and were intravenously challenged 5 wk laterwith
1,000 P. berghei (NK65) infectious sporozoites. This immu-
1085 Aggarwal et al.
nization provided protection in 55% of these animals, whereas
all of the unimmunized and 94% of the mice receiving the
WR4024 carrier strain were infected (Table 3). No antibody
in the serum of individual mice could be demonstrated against
recombinant CS protein using ELISA techniques (data not
shown) . Mice immunized intravenously with 50,000 irradi-
ated sporozoites were fully protected.
To determine the role of CD8+ T cells in protection,
mice were depleted of CD8' T cells by intraperitoneal in-
jections of anti-CD8 mAb 4 wk after immunization. This
procedure resulted in removal of >98% of the CD8+ T cells
from the spleens of these animals (data not shown). The deple-
tion was confirmed by surface phenotyping of CD8+ T cells
from the spleen by single-color indirect fluorescent staining
and monitored by microfluorometry. Elimination of CD8+
T cells abrogated the protection afterimmunization with the
Salmonella recombinant vaccine WR4024/pMGB2. Protec-
tion was reduced from 55% to 5% (Table 3). CD8+ T
cell-depleted control mice were all infected after challenge.
Mice depleted of CD4 T cells did not lose their immunity
(data not shown). These results indicate that CD8+ T cells
are the mediators of protection induced by Salmonella recom-
binant vaccines. However, in contrast to immunity induced
by Salmonella recombinant vaccines, immunity achieved by
immunization with radiation-attenuated sporozoites could
not be eliminated even after complete depletion of CD8+
T cells (Table 3).
To further characterize the CD8+ T cells induced by
Salmonella-P. berghei CS recombinant immunization, in vitro
cytotoxic T cell assays were performed. For these assays, we
used the methods ofTownsend et al. (27), where target cells
are made by incubation of histocompatible cells with short
synthetic peptides that associate with class I molecules. We
Table 1. Salmonella-CS Recombinant Vaccines
Immunogen Plasmid Gene Species
WR4024/pMGB2 pMGB2 Full-length CS P. berghei
WR4024/pADE171 R16 pADE171 Full-length CS P. falciparum
WR4024/pADE171 RLF pADE171 Flanking regions P. falciparum
WR4024 None None Carrier
Table 2. Plasmodium berghei CS Peptides
Sequence Region Residue
ADAPEGKKNEKKNEKIERNN NHz terminus 69-78
(DPPPPNPN)3 Repeat 102-124
NDDSYIPSAEKI COON terminus 242-253
SYIPSAEKILEFVKQQIRDSITEEWSQ COOH terminus 245-270
CFVKQIRDSITEEWSQCNVTCG COOH terminus 256-276R-16CSP
NS1 81RLF
pADE171
RECOMBINANT
Bglll BamH[
APL I RIB
￿
RI
￿
(NANP)37(NVDP)4
￿
R11
￿
ANCHOR
99111 BaMH1
￿
SalVmol
APL NS181 R1 R11
ECORI Hn0111
￿
ECORI
Aalil Pa11(E0g
Psll/SaII
Figure 1 .
￿
Construction of WR4024/phDE171 R16 and WR4024/
pADE171 RLF. The plasmid containing R16 full-length or NSI repeatless
CS gene ofP . fakiparum was digested with Bg1II and Sall . The gel-purified
insert was blunt-endligated into the Pstl site ofplasmid phDE171, which
carries his OGD region ofSalmonella, resulting in the plasmid containing
CS gene flanked by Salmonella his OGD .
designed peptides from the P . berghei CS protein based on
the sequence identified previously by Romero et al . (14) as
a CTL target . Five different peptides from NH2 terminus,
repeat region, and COOH terminus were used (Table 2) .
Spleen cells from mice immunized with either Salmonella-
P . berghei CS recombinant WR4024/pMGB2, S. typhimurium
carrier WR4024, or sporozoites were taken 4-10 wk after
immunization . After in vitro stimulation with peptide for
6 d, the killing was measured by the "Cr release .
Table 3 .
￿
Protective Immunity Induced by S. typhimurium
(WR4024) Transformed with a Plasmid Expressing Full-Length
P. berghei CS Gene (WR4024/pMGB2)
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The spleen cells from mice immunized with WR4024/
pMGB2 caused 24%D specific lysis of P815 (H-2d) target cells
incubatedwith peptide 242-253 at a concentration of50 NAg/ml
and anE/T ratio of 40:1 (Fig . 2) . Spleen cells from WR4024/
pMGB2-immunized mice had no Cytolytic activity without
in vitro peptide stimulation . In vitro stimulated cells did not
show activity ifthe target cells were not incubated with pep-
tide 242-253 . Spleen cells from unimmunized mice or mice
immunized with the carrier Salmonella WR4024 and stimu-
lated with the peptide 242-253 had <4%D cytolytic activity,
indicating that the CTL arose after immunization and were
not due to in vitro peptide stimulation. Specific Cytolytic ac-
tivity of34%D was measured with peptide 242-253-stimulated
spleen cells from miceimmunized with radiation-attenuated
sporozoites.
None of the other four peptides stimulated spleen cells from
mice immunized either with Salmonella recombinants or
radiation-attenuated sporozoites . These peptides also failed
to generate P815 cell targets. There was no specific lysis of
P815 cells after incubation with any of the five peptides at
the concentration used, demonstrating that they were not
directly toxic to cells . The CTL lytic activity generated by
WR4024/pMGB2 immunization was genetically restricted .
After stimulation of spleen cells with peptide 242-253, no
specific lytic activity was observed when EL4(H-26) cells in-
cubated with the same peptide were used as targets .
We asked whether Salmonella recombinant vaccines could
also induce CTL responses to the human malaria parasite
Pfalciparum . For this purpose, spleen cellsfrom B10 . BR(H-
2k) mice immunized with WR4024/pADE171 R16,
WR4024/pADE171 RLF, WR4024, or recombinant vac-
cinia (V-71) containing full-lengthP . fakiparum CS gene were
stimulated in vitro for 6 d with CS-transfected L cells (H-
2k) . These cells were then assessed for lytic activity against
transfected or untransfected L cells. At an E/T ratio of 40:1,
in three different sets ofexperiments, we observed 37 ± 2.2%
specific killing ofCS gene-transfected cells by CTL induced
by WR4024/pADE171 R16 compared with 20 ± 2.5%
40
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Figure 2 .
￿
Results of cytotoxic assays performed with P815 target cells
and CTL in the presence of synthetic peptides. Spleen cells from mice
immunized with Salmonella-P . berghei CS recombinant vaccine were stimu-
lated in vitro for 6 d with 50 Ag ofpeptide, and 6 d after in vitro stimula-
tion cells were incubated with 51Cr-labeled P815 cells in the presence of
different peptides, and 51Cr release was measured . This experiment is rep-
resentative of four independent experiments .
Immunogen
Anti-CD8
antibody
No . infected/
no . challenged
Percent
protection
WR40 - 29/31 6
WR4024 + 8/8 0
WR4024/pMGB2 - 10/22 55
WR4024/pMGB2 + 18/19 5
None - 30/30 0
None + 8/8 0
Irradiated Spz - 0/10 100
Irradiated Spz + 0/10 10050r
. 40
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A
A
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Figure 3 .
￿
Malaria Salmonella CS recombinants stimulate CS-specificCTL.
In vitro stimulated spleen cells from mice immunized with Salmonella-
P . falciparum CS recombinants were incubated with S'Cr-labeled CS-
transfected (A) or untransfected L cells (B) . Percent specific lysis was de-
termined . (0) Vaccinia CS recombinant ; (A) R16 ; (0) RLF ; (O) vector.
This experiment is representative of five independent experiments .
killing of untransfected L cells (p < 0.05) . Likewise, at this
E/T ratio, spleen cells from animals immunized with
WR4024/pADE171 RLF killed 36 ± 3.1% ofCS gene-trans-
fected L cells compared with 20 ± 4% killing of untrans-
fected L cells (p < 0.05) . These CTL responses were com-
parable with those obtained after immunization with the
recombinant vaccinia (Fig. 3) . CTLs from mice immunized
with the Salmonella carrier WR4024 gave 20 ± 4.5% 51Cr
release.
To determine if the cytotoxic activity in the spleen cell cul-
tures was due to CD8+ T cells, in vitro depletions were'per-
formed . Removal ofCD8+ T cells from the cultures on the
day ofthe CTL assay was confirmed byMF (data not shown) .
WR4024/pADE171 R16-induced CS-specific CTL, when
treated with anti-CD8 mAb and complement, yielded only
5 ± 2.8% specific lysis of CS-specific target cells at an E/T
ratio of 40:1 compared with specific lysis of 37 ± 2.2% (p
< 0.05), when the cells were treated with complement alone
(Fig. 4) . WR4024/pADE171 RLF induced CTL with similar
activity (12 ± 3.5 vs. 36 ± 3.1 ; p < 0.05) . This demon-
strated that the CS-specific cytotoxicity was mediated by
CD8+ cells . Reductions in specific cytotoxicity by depletion
of CD8+ T cells were similar for spleen cells from animals
immunized with each of the three vaccines (Fig . 4) .
Immunization of B10.BR mice with Salmonella also in-
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duced CTL that caused 20 ± 4.5% lysis of untransfected
cells. This nonspecific effect was induced by both recombinants
and the control Salmonella vaccine, and contrasts to the 7 ±
1.5% lysis seen with recombinant vaccinia-immunized mice
(Fig . 3) . After CD8 depletion, the lysis of untransfected cells
by WR4024/pADE R16-induced CTL was reduced from
18 ± 2.8 to 4 ± 2% (p < 0.05), and killing by WR4024/
pADE171 RLF-induced CTL was reduced from 16 ± 3 .5
to 7 ± 1.5% (p < 0.05) . These findings suggest that the
majority of induced nonspecific cytotoxicT cells were CD8+
(Fig. 4) . Immunization ofBALB/c mice with Salmonella vac-
cines followed by in vitro stimulation of spleen cells with
peptides did not yieldCTL reactive with non-peptide-pulsed
targets. Thismay be attributed to differences between in vitro
stimulation with transfected cells vs . in vitro stimulation with
peptides .
To determine the epitope specificity of CTL induced by
oral immunization with Salmonella-P . fakiparum CS constructs
in B10.BR mice, spleen cells from immunized mice were
stimulated in vitro with CS-transfected L cells. After 6 d,
untransfectedL cells were incubated with 10014g/ml ofpep-
tide 371-390, single letter code DELDYENDIEKKICK-
MEKCSS, or peptide 291-310 from theP .falciparum CS gene
(12), and lysis was determined at an E/T of 40:1 . Peptide
with amino acid sequence 371-390 was recognized by CTL
from mice immunized with the two recombinant Salmonella
vaccines or the recombinant vaccinia (Fig . 5) . This same peptide
had previously been identified as the target of CTL induced
by sporozoite or recombinant vaccinia-CS immunization (12) .
L cells incubated with peptide 291-310 were not lysed by
immune CTL above the levels seen with target cells alone
(data not shown) .
Discussion
We have demonstrated that oral immunization of mice with
attenuated S. typhimurium recombinants expressing full-length
P . berghei CS gene or full-length or repeatless P . fakiparum
CS gene induce specific CD8+ CTL . We also provide evi-
dence that these CS-specificCTL are responsible for the pro-
tection induced against P . berghei sporozoites after immuni-
zation ofBALB/c mice with Salmonella recombinant vaccines .
Antibody-dependent cellular cytotoxicity has been shown
after immunization of humans with S. tpphi mutant strain
Figure 4.
￿
Effect of CD8 depletion on CS-specific
CTL . Invitro stimulated cells from themiceimmunized
with Salmonella-P .falciparum CS recombinants were in-
cubated with anti-CD8 mAb (19/178) followed by com-
plement . Washed cells were then incubated with 5,000
5'Cr-labeled transfected (A) or untransfected (B) L cells
at various E/T ratios. The percent specific lysis oftarget
cells by complement-treated (/) or CD8-depleted (®)
CTL was determined . A representative experiment at
the 40 :1 ratio is presented .Figure 5 .
￿
Identification oftheCTL epitope on theP .fakiparum CS pro-
tein . Spleen cells from Salmonella-P . fakiparum recombinant-immunized
mice were stimulated in vitro with CS-transfected L cells . S'Cr-labeled
target cells were incubated with peptide and the in vitro stimulated spleen
cells at an E/T ratio of40 :1 (N) ; or without peptide (®), and S1Cr re-
lease was measured . This experiment is representative of three indepen-
dent experiments .
Ty21a (28) or auxotrophic S. typhi 541Ty(Vi+) or 543Ty(Vi-)
(29) . The effector cell has been identified as a nonadherent
T3 + , T8 - , T4+ lymphocyte (28) . After immunization,
delayed-type hypersensitivity responses to Salmonella carbo-
hydrate antigens (30) and recombinant expressed proteins have
been demonstrated (15, 31) . Macrophage activation directly
or through T cell-mediated mechanisms has also been seen
after immunization or infection (32, 33) . To our knowledge,
induction of protective class I-restricted antigen-specific
CD8+ CTL by immunization or infection with Salmonella
has not, however, been previously reported .
After oral ingestion, attenuated Salmonella vaccines are soon
translocated from the intestinal lumen to an intracellular lo-
cation, primarily inside macrophages (30) . Attenuated Sal-
monella carrier strains, such as S. typhimurium WR4024 used
in this study and the aro A mutant of S. dublin SL1438 used
by us in other studies (34), have limited ability to multiply
within macrophages but do survive for variable periods of
time . The intracellular expression ofrecombinant malariaCS
antigens is probably responsible for processing and presenta-
tion in association with class I antigen with the subsequent
induction ofCTL . Bacterial enzymes may play some role in
degradation of the recombinant expressed protein before pro-
cessing by intracellular enzymes, although we have no direct
evidence for this possibility. The presence of Salmonella in-
side macrophages may also activate these macrophages and
induce the release of cytokines thought to be important as
differentiation factors for induction of CTL (35) .
Until recently, it was generally thought that viruses were
the only pathogens capable of presenting endogenous antigens
on the surface ofinfected cells in association with class I mol-
ecules with the subsequent induction of CD8+ CTL . This
view was challenged by the evidence for a protective role of
CD8+ CTL induced by sporozoites in murine malaria (10,
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11), induction of CTL in mice against P . falciparum CS by
sporozoites (13), and the protective role of CD8+ T cells in
immunity to Toxoplasma gondii (36) . There is also evidence
that protection against intracellular pathogens such asL . mono-
cytogenes,M . tuberculosis, M . leprae, and others may in part
be mediated through CD8+ T cells (37) . Our findings
directly prove that an intracellular bacteria such as S. typhimu-
rium can induce specific CD8+ CTL and suggest that the
antigen processing and presentation is probably not very
different from that which occurs with vaccinia or sporozoites,
since the recognized peptide and quantitative data are very
similar.
Our finding that Salmonella-P . bergheiCS recombinant-in-
duced protection is mediated through specific CD8+ cyto-
toxic T cells further demonstrates the importance of CTL
in immunity against malaria . This is consistent with the re-
cent finding that CD8+ CTL clones directed against P . ber-
ghei CS by themselves are able to provide complete protec-
tion (14) . These CTL clones were induced by immunization
with radiation-attenuated sporozoites. TheCTL we induced
with Salmonella CS recombinants are directed against the same
peptide in the CS sequence as the CTL clones defined by
Romero et al. (14) . Not all of the CTL clones found by
Romero were able to protect . Our study demonstrates that
at least some of the CTL induced by Salmonella-P . berghei
CS recombinants are protective. To increase the number of
protectiveCTL induced by oral immunization with Salmonella
CS recombinants, we are inserting malarial genes into the
bacterial chromosome in an attempt to stabilize and increase
the expression of malaria gene products . We are also utilizing
Salmonella auxotrophs as carrier strains, which are safe but
more invasive than the attenuated S. typhimurium WR4024
we utilized in this study.
We were able to achieve CTL that gave similar levels of
killing by immunization with Salmonella-P . fakiparum CS
recombinant vaccines that expressed the entire CS gene or
a gene from which the central repeat region was deleted . Both
of these recombinant constructs produced the malariaCS an-
tigens as fusion proteins . The complete CS molecule is there-
fore not required for the in vivo induction of CD8+ CTL
by Salmonella, and modification of the original geneby addi-
tion also does not interfere . Presentation of antigens in as-
sociation with class I molecules is generally dependent on
intracellular enzymatic cleavage to produce a peptide frag-
ment that can bind to the class I molecule. Our findings sug-
gest a possible method for determining the minimal struc-
ture from any given molecule that is necessary for such a process
to occur. This could be done by cloning deletion fragments
as fusion proteins into Salmonella and looking for the ability
of these Salmonella recombinants to induce CTL .
We were able to determine the Salmonella-P . berghei CS
recombinant-induced protection by depletion of CD8+ T
cells . This contrasts with our inability to eliminate protec-
tion by this technique in BALB/c mice immunized with
radiation-attenuated sporozoites. This result may be due to
involvement of antibody, effector CD4+ T cells, other im-
mune cell types or other sporozoite or preerythrocytic an-
tigens in BALB/c immunity toP . berghei. Schofield et al . (11)were able to eliminate sporozoite-induced protection in A/J
mice by depletion of CD8+ T cells. This shows that the
mechanism of radiation in attenuated sporozoite-induced im-
munity is dependent on the mouse haplotype. Although we
were not able to eliminate sporozoite-induced protection in
BALB/c mice, Weiss et al. (10) were able to accomplish this,
but the parasite was P. yoelii.
A vaccine for malaria that overcomes the sequence varia-
tion in the CS CTL site as well as differences due to genetic
restriction (13) will likely contain several different versions
of the CS CTL site recognized by humans as well as other
sporozoite and liver stage antigens important for CTL rec-
ognition. Such multivalent vaccines can be constructed in
Salmonella because of the size of the bacterial genome and
the flexibility of its manipulation. Because new Salmonella
vaccine strains designed for human use are auxotrophs (38),
which can only replicate in the body to a limited extent, they
have been safe in studies of immunocompromised hosts (39,
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